Navigation Links
Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity
Date:5/31/2011

MOUNTAIN VIEW, Calif., May 31, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented over the weekend at the European Congress on Obesity (ECO) in Istanbul, Turkey.  ECO is the official obesity congress of The European Association for the Study of Obesity (EASO). ECO is regularly attended by more than 2500 participants from over 75 countries and is considered to be the most important annual scientific event on obesity in Europe.  

Highlights from the ECO presentations were as follows:

A poster presentation authored by W. Timothy Garvey, MD from the University of Alabama at Birmingham reported reductions in progression to type 2 diabetes and improvement in glycemic status in CONQUER patients that were ADA-defined as prediabetics at baseline.  Of the 2,487 patients in the CONQUER study, 1,119 were determined to have prediabetes.  In the prediabetics treated with QNEXA, hemoglobin A1c, fasting glucose and fasting insulin were significantly improved at week 56 (ITT-LOCF p<0.005 vs. placebo).  In the prediabetic population significantly more QNEXA treated patients achieved normal blood sugar levels (p=0.0016) and significantly more patients on placebo were progressed to type 2 diabetics as compared to the QNEXA treated patients (p=0.0253).  

"For this set of patients, QNEXA treatment led to benefits above and beyond losing weight.  The results highlighted by Dr Garvey showed that weight loss after 56 weeks of treatment led to an improvement in glycemic status and reduction of progression to type 2 diabetes.  This clinically important finding further strengthens the QNEXA benefit profile," added Barbara Troupin, MD, senior director of medical affairs for VIVUS.  

The CONQUER study included 2,487 patients that had two or more comorbidities studied over 56 weeks. 
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Hope Paige Designs Medical ID Bracelets Now Available in 1,100 Additional Locations
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. Omeros Reports Allowance of Additional Patent for Arthroscopic Product
4. Cynosure Receives Additional International Regulatory Approvals for New Cellulite Reduction Workstations
5. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
6. Rosetta Genomics Announces Issuance of Additional U.S. Patent
7. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
8. Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
9. Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010
10. Additional 8 Products of DK Sinopharma, Inc. are Included in 2010 Provincial Medical Insurance Catalogs in 4 Separate Provinces in the Peoples Republic of China
11. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. announced ... 2 clinical program of NP001 for the treatment of ... disease) are being highlighted today in an oral presentation ... Group , being held in Bloomington, Minnesota ... hoc  analysis, administration of a high dose of NP001 ...
(Date:9/17/2014)... 17 2014 IBM (NYSE: IBM ) ... IBM technical computing and storage technology to accelerate ... These services deliver critically important information to help ... unique cancer, which could lead to better health ... in general. Today, optimal cancer care ...
(Date:9/17/2014)... , September 17, 2014 ... to congratulate Biocartis commitment in shipping its first ... long-time investor in Biocartis as part of Debiopharm ... fully automated, real-time PCR based molecular diagnostics system, ... access to clinical molecular diagnostic information, anywhere and ...
Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 2Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 4Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument 2
... - NanoViricides,Inc. (Pink Sheets: NNVC) discussed today the ... presented along with the,successful BSL3 in vitro studies ... Annual Symposium of the Pan American Society for ... (Pan American Society,for Clinical Virology (PASCV): Clinical Virology ...
... and Symptom Severity; New,Resources for Patients, Parents, WASHINGTON, ... today by the National Consumers League shows that ... days. Four in,ten asthma sufferers understand asthma medication ... recent the diagnosis, the less,knowledgeable adult patients tend ...
Cached Medicine Technology:Global Rabies Treatment May be Possible with NanoViricides Drugs 2New Survey Finds Troubling Data on American Asthma Sufferers 2New Survey Finds Troubling Data on American Asthma Sufferers 3New Survey Finds Troubling Data on American Asthma Sufferers 4New Survey Finds Troubling Data on American Asthma Sufferers 5New Survey Finds Troubling Data on American Asthma Sufferers 6
(Date:9/17/2014)... York (PRWEB) September 17, 2014 The ... increase in worth due to the key driving factors ... advancements. An expected CAGR of 8.2 % puts the ... $730.2 million in 2018, as stated in a Transparency ... Industry Analysis, Size, Share, Growth, Trends, and Forecast 2012 ...
(Date:9/17/2014)... news release is available in Spanish . ... affect more than half of the population in our ... one of which affects liver function. Fat accumulates in ... causes inflammation, fibrosis and finally, cirrhosis. To date, the ... hepatic biopsy. Imaging techniques such as abdominal ecography detect ...
(Date:9/17/2014)... of America (GSA) invites all journalists to attend ... country,s largest interdisciplinary conference in the field of aging ... Media representatives may register free of charge. , An ... gathering at the Walter E. Washington Convention Center and ... "Making Connections: From Cells to Societies" and the program ...
(Date:9/17/2014)... Representatives with Capitol Pain Institute announced ... League Event at the Four Seasons in Austin, Texas. , ... honor to be a sponsor for this great event,” said ... went on to explain that the event, the Torch of ... members at the Four Seasons to honor Torch of Liberty ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Neon Sport ... part in the fitness industry’s most anticipated event, Joe ... NV. Two fans will each take home a Neon ... Neon Sport supplements and gear. Fitmark will hold entries ... Olympia Expo, September 19-20th. , “There’s nothing more ...
Breaking Medicine News(10 mins):Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 2Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 3Health News:Magnetic resonance helps to detect and quantify fat in liver 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2
... ... Pricing Discount! , ... UK (PRWEB) May 12, 2010 -- Citywide Cleaning Services - a division of Citywide Ventures ... 10% pricing discount on any new cleaning contracts. Also, the Company announced that it will ...
... pattern that predicts the likelihood of relapse in patients ... leukemia has been discovered. Researchers publishing in the open ... consistent pattern in five genes that has the potential ... from more aggressive treatment when first diagnosed with T-cell ...
... ... features allow even more companies to save money through better contract management by reduciing ... ... -- Network Contract Solutions has released new features allowing holding companies to take advantage ...
... allergy even exist, researchers find , TUESDAY, May ... information about the prevalence, diagnosis and treatment of food ... studies. , The articles looked at allergies to cow,s ... which account for more than 50 percent of all ...
... Center announced today that it has received a US$100,000 ... Gates Foundation. The grant will support an innovative ... assistant professor in the Department of Microbiology and Immunology, ... Immune Intervention." Joshi,s project is one of 78 ...
... goal of a secure nationwide health information network (NHIN), a ... evaluating the costs, effort and value of what is sometimes ... which appears in the May/June 2010 issue of Journal ... the initial assessment of that framework by health information exchange ...
Cached Medicine News:Health News:Cleaning Service Pricing Discount 2Health News:Genetic pattern that predicts leukemia relapse discovered 2Health News:Network Contract Solutions Adds Holding Company Features to Extend Market Reach and Client Base 2Health News:Few High-Quality Studies on Food Allergies, Say Reviewers 2Health News:OUHSC receives $100,000 Grand Challenges Explorations grant for innovative global health research 2Health News:Measuring success: Regenstrief helps assess value of investment in health info tech 2
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
For the qualitative detection of Wuchereria bancrofti antigen in whole blood, serum and plasma specimens...
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
Medicine Products: